FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947172089> ?p ?o ?g. }

• W2947172089 endingPage "4001" @default.
• W2947172089 startingPage "4001" @default.
• W2947172089 abstract "4001 Background: Adjuvant chemotherapy and/or chemoradiotherapy have been the standard of care in GC for years, supported by randomized trials. We compared the efficacy of different chemotherapy regimens and chemoradiotherapy in patients with D2-resected, stage II/III, node-positive GC. Methods: From Feb 2013 through Nov 2018, we randomly assigned, in a 1:1:1 ratio, patients with pathologically-staged II or III, node-positive, D2-resected GC, to receive adjuvant S-1 (40-60 mg twice daily 4-weeks-on/2-weeks-off) for one year, S-1 (2-weeks-on/1-week-off) plus oxaliplatin 130 mg/m2 (SOX) for six months, or SOX plus chemoradiotherapy 45 Gy (SOXRT). Randomization was stratified according to the type of surgery (total or subtotal gastrectomy), stage (II or III), and Lauren histologic classification (diffuse or intestinal). The primary endpoint was disease-free survival (DFS). A total of 900 patients had to be enrolled to demonstrate superiority of SOX or SOXRT to S-1 (hazard ratio [HR] 0.667), with 90% power at a two-sided significance level of 5%. Results: A total of 538 patients were included for this interim efficacy analysis. Median age was 58 years, men constituted 65%, and stage II and III were 31% and 69%, respectively. Baseline tumor and patient characteristics were balanced between treatment arms. Adverse events were as anticipated in each arm, generally well-tolerated and manageable. DFS in the control arm (S-1) were significantly shorter than in SOX and SOXRT arms (stratified HR for recurrence): S-1 vs. SOX, 0.617 (P = 0.016) and S-1 vs. SOXRT, 0.686 (P = 0.057). The DFS at 3-years was found to be 65%, 78% and 73% in S-1, SOX and SOXRT arms, respectively. No difference in DFS between SOX and SOXRT was found (HR 0.910, P = 0.667). Based on the results after the observation of 145 recurrence events at the cutoff date of Dec 27, 2018, the independent data monitoring committee considered the results sufficient to meet the endpoint of the trial and recommended early stopping of the trial. Conclusions: In patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared to S-1 monotherapy. Clinical trial information: NCT0176146." @default.
• W2947172089 created "2019-06-07" @default.
• W2947172089 creator A5005620849 @default.
• W2947172089 creator A5010509952 @default.
• W2947172089 creator A5010774643 @default.
• W2947172089 creator A5011928803 @default.
• W2947172089 creator A5014451544 @default.
• W2947172089 creator A5017366532 @default.
• W2947172089 creator A5018452728 @default.
• W2947172089 creator A5018855985 @default.
• W2947172089 creator A5019308668 @default.
• W2947172089 creator A5019406140 @default.
• W2947172089 creator A5025322881 @default.
• W2947172089 creator A5030467675 @default.
• W2947172089 creator A5032561728 @default.
• W2947172089 creator A5046672787 @default.
• W2947172089 creator A5057146015 @default.
• W2947172089 creator A5065244228 @default.
• W2947172089 creator A5072048377 @default.
• W2947172089 creator A5075932421 @default.
• W2947172089 creator A5084870834 @default.
• W2947172089 date "2019-05-20" @default.
• W2947172089 modified "2023-10-11" @default.
• W2947172089 title "ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC)." @default.
• W2947172089 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.4001" @default.
• W2947172089 hasPublicationYear "2019" @default.
• W2947172089 type Work @default.
• W2947172089 sameAs 2947172089 @default.
• W2947172089 citedByCount "50" @default.
• W2947172089 countsByYear W29471720892019 @default.
• W2947172089 countsByYear W29471720892020 @default.
• W2947172089 countsByYear W29471720892021 @default.
• W2947172089 countsByYear W29471720892022 @default.
• W2947172089 countsByYear W29471720892023 @default.
• W2947172089 crossrefType "journal-article" @default.
• W2947172089 hasAuthorship W2947172089A5005620849 @default.
• W2947172089 hasAuthorship W2947172089A5010509952 @default.
• W2947172089 hasAuthorship W2947172089A5010774643 @default.
• W2947172089 hasAuthorship W2947172089A5011928803 @default.
• W2947172089 hasAuthorship W2947172089A5014451544 @default.
• W2947172089 hasAuthorship W2947172089A5017366532 @default.
• W2947172089 hasAuthorship W2947172089A5018452728 @default.
• W2947172089 hasAuthorship W2947172089A5018855985 @default.
• W2947172089 hasAuthorship W2947172089A5019308668 @default.
• W2947172089 hasAuthorship W2947172089A5019406140 @default.
• W2947172089 hasAuthorship W2947172089A5025322881 @default.
• W2947172089 hasAuthorship W2947172089A5030467675 @default.
• W2947172089 hasAuthorship W2947172089A5032561728 @default.
• W2947172089 hasAuthorship W2947172089A5046672787 @default.
• W2947172089 hasAuthorship W2947172089A5057146015 @default.
• W2947172089 hasAuthorship W2947172089A5065244228 @default.
• W2947172089 hasAuthorship W2947172089A5072048377 @default.
• W2947172089 hasAuthorship W2947172089A5075932421 @default.
• W2947172089 hasAuthorship W2947172089A5084870834 @default.
• W2947172089 hasConcept C121608353 @default.
• W2947172089 hasConcept C126322002 @default.
• W2947172089 hasConcept C141071460 @default.
• W2947172089 hasConcept C146357865 @default.
• W2947172089 hasConcept C151730666 @default.
• W2947172089 hasConcept C168563851 @default.
• W2947172089 hasConcept C203092338 @default.
• W2947172089 hasConcept C204243189 @default.
• W2947172089 hasConcept C207103383 @default.
• W2947172089 hasConcept C2776694085 @default.
• W2947172089 hasConcept C2778424827 @default.
• W2947172089 hasConcept C2780470880 @default.
• W2947172089 hasConcept C2780962732 @default.
• W2947172089 hasConcept C44249647 @default.
• W2947172089 hasConcept C526805850 @default.
• W2947172089 hasConcept C61943457 @default.
• W2947172089 hasConcept C71924100 @default.
• W2947172089 hasConcept C86803240 @default.
• W2947172089 hasConcept C90924648 @default.
• W2947172089 hasConceptScore W2947172089C121608353 @default.
• W2947172089 hasConceptScore W2947172089C126322002 @default.
• W2947172089 hasConceptScore W2947172089C141071460 @default.
• W2947172089 hasConceptScore W2947172089C146357865 @default.
• W2947172089 hasConceptScore W2947172089C151730666 @default.
• W2947172089 hasConceptScore W2947172089C168563851 @default.
• W2947172089 hasConceptScore W2947172089C203092338 @default.
• W2947172089 hasConceptScore W2947172089C204243189 @default.
• W2947172089 hasConceptScore W2947172089C207103383 @default.
• W2947172089 hasConceptScore W2947172089C2776694085 @default.
• W2947172089 hasConceptScore W2947172089C2778424827 @default.
• W2947172089 hasConceptScore W2947172089C2780470880 @default.
• W2947172089 hasConceptScore W2947172089C2780962732 @default.
• W2947172089 hasConceptScore W2947172089C44249647 @default.
• W2947172089 hasConceptScore W2947172089C526805850 @default.
• W2947172089 hasConceptScore W2947172089C61943457 @default.
• W2947172089 hasConceptScore W2947172089C71924100 @default.
• W2947172089 hasConceptScore W2947172089C86803240 @default.
• W2947172089 hasConceptScore W2947172089C90924648 @default.
• W2947172089 hasIssue "15_suppl" @default.
• W2947172089 hasLocation W29471720891 @default.
• W2947172089 hasOpenAccess W2947172089 @default.
• W2947172089 hasPrimaryLocation W29471720891 @default.
• W2947172089 hasRelatedWork W167319750 @default.
• W2947172089 hasRelatedWork W2242099312 @default.

• next